Skip to search formSkip to main contentSkip to account menu

NE 58095

Known as: NE-58095 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (3)

Etidronic AcidRisedronaterisedronate sodium
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
History of risedronate.
2018
2018
Phase Ⅰ Clinical Trial of NE-58095 DR, a Risedronate Delayed-Release Tablet: Dose Escalation and Food Effect
Risedronate has been indicated for the treatment of osteoporosis and Pagetʼs disease of bone in many countries. Risedronate… 
1998
1998
Risedronate Norwich-Eaton Pharmaceuticals Inc.
  • P. Norman
  • IDrugs : the investigational drugs journal
  • 1998
  • Corpus ID: 33754827
Risedronate (NE-58095) is a third generation bisphosphonate bone-resorption inhibitor and osteogenesis stimulator under… 
Highly Cited
1997
Highly Cited
1997
A 2-Year Phase II Study with 1-Year of Follow-up of Risedronate (NE-58095) in Postmenopausal Osteoporosis
Abstract: This paper presents the results of a two-center, double-masked, placebo-controlled, randomized, oral-dose study of… 
Highly Cited
1995
Highly Cited
1995
Risedronate treatment does not increase microdamage in the canine femoral neck.
Review
1994
Review
1994
Effect of the bisphosphonate risedronate on bone metastases in a rat mammary adenocarcinoma model system
Risedronate (NE‐58095) is a third‐generation bisphosphonate with very potent antiresorptive activity but few toxic effects. The… 
Highly Cited
1991
Highly Cited
1991
Estrogen and diphosphonate treatment provide long‐term protection against osteopenia in ovariectomized rats
The goal of this study is to determine whether the previously observed, short‐term protective effect of estrogen and… 
Highly Cited
1989
Highly Cited
1989
NE-58095: a diphosphonate which prevents bone erosion and preserves joint architecture in experimental arthritis.
The rat adjuvant arthritis model, like human rheumatoid arthritis, is characterized by fulminating intra- and periarticular… 
Highly Cited
1989
Highly Cited
1989
Endocrine and pharmacological suppressors of bone turnover protect against osteopenia in ovariectomized rats.
This study was designed to test the hypothesis that endocrine and pharmacological suppressors of bone turnover prevent the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)